Scientists Develop New Technique to Deliver Vaccines without Needles

In this May 5, 2022, file photo, a nurse administers the Pfizer booster shot at a COVID-19 vaccination and testing site in Los Angeles. Frederic J. Brown/AFP via Getty Images, FILE
In this May 5, 2022, file photo, a nurse administers the Pfizer booster shot at a COVID-19 vaccination and testing site in Los Angeles. Frederic J. Brown/AFP via Getty Images, FILE
TT

Scientists Develop New Technique to Deliver Vaccines without Needles

In this May 5, 2022, file photo, a nurse administers the Pfizer booster shot at a COVID-19 vaccination and testing site in Los Angeles. Frederic J. Brown/AFP via Getty Images, FILE
In this May 5, 2022, file photo, a nurse administers the Pfizer booster shot at a COVID-19 vaccination and testing site in Los Angeles. Frederic J. Brown/AFP via Getty Images, FILE

British researchers announced that they have developed a new technique that delivers vaccines in the body without needles. The technique could help deliver vaccines through the skin via ultrasounds without using needles that harm the skin and cause pain. The findings were presented at an international conference in Australia on Monday.

An estimated quarter of adults and two-thirds of children have strong fears around needles, according to the US Centers for Disease Control and Prevention. Yet, public health depends on people being willing to receive vaccines, which are often administered by a jab.

The new method relies on ultrasound pulses to form small bubbles that clear passages through the skin. Then, the pulses deliver the vaccine molecules through the bubbles, which allows its diffusion in the surrounding tissues.

“Our method relies on an acoustic effect called ‘cavitation,’ which is the formation and popping of bubbles in response to a sound wave,” said Darcy Dunn-Lawless, lead author from the University of Oxford’s Institute of Biomedical Engineering.

“We aim to harness the concentrated bursts of mechanical energy produced by these bubble collapses in three main ways. First, to clear passages through the outer layer of dead skin cells and allow vaccine molecules to pass through. Second, to act as a pump that drives the drug molecules into these passages. Lastly, to open up the membranes surrounding the cells themselves, since some types of vaccine must get inside a cell to function,” she explained.

Initial in vivo tests reported that the vaccine molecules delivered by the new approach produced a higher immune response, according to the Eurekalert website.

The researchers theorize this could be due to the immune-rich skin the ultrasonic delivery targets in contrast to the muscles that receive the jab.

According to Lawless, the result is a more efficient vaccine that could help reduce costs and increase efficacy with little risk of side effects. The team plans further research to explore the efficacy and safety of the new approach for specific vaccines like DNA vaccines.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”